Key PointsA director of Enliven Therapeutics reported selling 10,000 shares in open-market transactions on June 5, 2026, for a total value of $345,000.The sale represented 16.16% of Lori Anne Kunkel’s direct common stock holdings, reducing her position from 61,884 to 51,884 shares.All shares involved were held directly; there was no indirect ownership or derivative security activity.10 stocks we like better than Enliven Therapeutics › Lori Anne …